BFRG

0.35568.84%
ER

Eric Roos

SVP of Business Development & Corporate Strategy

Mr. Eric Roos is SVP of Business Development & Corporate Strategy of Bullfrog AI Holdings, Inc. from June 2026. He is a seasoned biotech executive with extensive track record that triangulates therapeutic technical innovation with high-value corporate strategy, enterprise business development and strategic commercial partnerships. Mr. Roos possesses a rare blend of expertise as a pioneer of patented and scaled advanced therapeutic platforms before he transitioned into the executive suite leading multi-billion-dollar global alliances. He served as a Scientific Advisor at BullFrog AI Holdings, Inc until September 2023. He had been Chief Business Development Officer at Aspect Biosystems Ltd. since May 2020 until October 2025. Mr. Roos served as Vice President of Process and Product Development at Histogenics Corporation. Mr. Roos has maintained a variety of responsibilities since joining Histogenics, including establishing the initial NeoCart facility and the manufacturing, quality, clinical and regulatory systems to support early phase clinical trial execution and process optimization. He has extensive experience in product development, process development and operations at early stage ventures in the fields of tissue engineering, biomaterials and drug delivery. He spent the first decade of his career applying drug delivery, formulation and materials science principles to the development of transdermal systems, growth factor formulations and environmentally responsive hydrogels. Prior to joining the Histogenics founding team in 2003, Mr. Roos developed tissue engineering technologies for encapsulated cell therapy and neural stem cells at Cytotherapeutics, wound healing at Organogenesis and cardiac repair at Bioheart. He has authored a number of patents and publications in the fields of tissue engineering, drug delivery and biomaterials. Mr. Roos holds a B.Sc. in Biochemistry from McGill University.

Positions